BioCryst Pharmaceuticals BCRX Finance Lease Liabilities
Finance Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityNoncurrent.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's finance lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's finance lease liabilities?
- BioCryst Pharmaceuticals (BCRX) reported finance lease liabilities of $1.17M in Q1 2026.
- How has BioCryst Pharmaceuticals's finance lease liabilities changed year-over-year?
- BioCryst Pharmaceuticals's finance lease liabilities decreased by 49.3% year-over-year, from $2.31M to $1.17M.
- What is the long-term trend for BioCryst Pharmaceuticals's finance lease liabilities?
- Over 4 years (2020 to 2025), BioCryst Pharmaceuticals's finance lease liabilities has grown at a -21.9% compound annual growth rate (CAGR), from $3.87M to $1.44M.
- What does finance lease liabilities mean?
- Present value of future payments on leases classified as finance leases under ASC 842 — treated similarly to debt on the balance sheet.